Evidence map›Paper›PMID 36535825›Full record

ArticleVaccine2023

A broad assessment of covid-19 vaccine safety using tree-based data-mining in the vaccine safety datalink.

W Katherine Yih, Matthew F Daley, Jonathan Duffy, Bruce Fireman, David McClure, Jennifer Nelson, Lei Qian, Ning Smith, Gabriela Vazquez-Benitez, Eric Weintraub and 3 more

Abstract read
In one paragraph

Article in Vaccine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Neonatal and Infant Health Outcomes Following Maternal COVID-19 Vaccination: CDC's COVID-19 Vaccine Pregnancy Registry.Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Comparison of Venous Thromboembolism Outcomes after COVID-19 and Influenza Vaccinations.TH open : companion journal to thrombosis and haemostasis · 2023
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

W Katherine YihHarvard Pilgrim Health Care Institute and Department of Population Medicine, Harvard Medical School, Boston, MA, United States.
Matthew F DaleyKaiser Permanente Colorado, Aurora, CO, United States.
Jonathan DuffyImmunization Safety Office, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Bruce FiremanKaiser Permanente Northern California, Oakland, CA, United States.
David McClureMarshfield Clinic Research Institute, Marshfield, WI, United States.
Jennifer NelsonKaiser Permanente Washington, Seattle, WA, United States.
Lei QianKaiser Permanente Southern California, Pasadena, CA, United States.
Ning SmithKaiser Permanente Northwest, Portland, OR, United States.
Gabriela Vazquez-BenitezHealthPartners Institute, Bloomington, MN, United States.
Eric WeintraubImmunization Safety Office, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Joshua T B WilliamsDenver Health, Denver, CO, United States.
Stanley XuKaiser Permanente Southern California, Pasadena, CA, United States.
Judith C MaroHarvard Pilgrim Health Care Institute and Department of Population Medicine, Harvard Medical School, Boston, MA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExcept for spontaneous reporting systems, vaccine safety monitoring generally involves pre-specifying health outcomes and post-vaccination risk windows of concern. Instead, we used tree-based data-mining to look more broadly for possible adverse events after Pfizer-BioNTech, Moderna, and Janssen COVID-19 vaccination.

methodsVaccine Safety Datalink enrollees receiving ≥1 dose of COVID-19 vaccine in 2020-2021 were followed for 70 days after Pfizer-BioNTech or Moderna and 56 days after Janssen vaccination. Incident diagnoses in inpatient or emergency department settings were analyzed for clustering within both the hierarchical ICD-10-CM code structure and the post-vaccination follow-up period. We used the self-controlled tree-temporal scan statistic and TreeScan software. Monte Carlo simulation was used to estimate p-values; p = 0.01 was the pre-specified cut-off for statistical significance of a cluster.

resultsThere were 4.1, 2.6, and 0.4 million Pfizer-BioNTech, Moderna, and Janssen vaccinees, respectively. Clusters after Pfizer-BioNTech vaccination included: (1) unspecified adverse effects, (2) common vaccine reactions, such as fever, myalgia, and headache, (3) myocarditis/pericarditis, and (4) less specific cardiac or respiratory symptoms, all with the strongest clusters generally after Dose 2; and (5) COVID-19/viral pneumonia/sepsis/respiratory failure in the first 3 weeks after Dose 1. Moderna results were similar but without a significant myocarditis/pericarditis cluster. Further investigation suggested the fifth signal group was a manifestation of mRNA vaccine effectiveness after the first 3 weeks. Janssen vaccinees had clusters of unspecified or common vaccine reactions, gait/mobility abnormalities, and muscle weakness. The latter two were deemed to have arisen from confounding related to practices at one site.

conclusionsWe detected post-vaccination clusters of unspecified adverse effects, common vaccine reactions, and, for the mRNA vaccines, chest pain and palpitations, as well as myocarditis/pericarditis after Pfizer-BioNTech Dose 2. Unique advantages of this data mining are its untargeted nature and its inherent adjustment for the multiplicity of diagnoses and risk intervals scanned.

Indexed as

COVID-19COVID-19 VaccinesDrug-Related Side Effects and Adverse ReactionsMyocarditisCluster AnalysisData MiningHumansCOVID-19 Vaccines

Identifiers

PMID36535825
PMCPMC9755007

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.